Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.
Identifieur interne : 001B39 ( PubMed/Curation ); précédent : 001B38; suivant : 001B40Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.
Auteurs : J. Rogers [États-Unis] ; R J Schoepp ; O. Schröder ; T L Clements ; T F Holland ; J Q Li ; J. Li ; L M Lewis ; R P Dirmeier ; G J Frey ; X. Tan ; K. Wong ; G. Woodnutt ; M. Keller ; D S Reed ; B E Kimmel ; E C TozerSource :
- Protein engineering, design & selection : PEDS [ 1741-0126 ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (génétique), Anticorps antiviraux (isolement et purification), Anticorps antiviraux (usage thérapeutique), Cellules Vero, Découverte de médicament, Humains, Maladies transmissibles émergentes (), Mutation ponctuelle (immunologie), Souris, Souris de lignée BALB C, Spécificité des anticorps (immunologie), Syndrome respiratoire aigu sévère (), Tests de neutralisation, Virus du SRAS (immunologie), Évolution moléculaire dirigée ().
- MESH :
- génétique : Anticorps antiviraux.
- immunologie : Mutation ponctuelle, Spécificité des anticorps, Virus du SRAS.
- isolement et purification : Anticorps antiviraux.
- usage thérapeutique : Anticorps antiviraux.
- Animaux, Cellules Vero, Découverte de médicament, Humains, Maladies transmissibles émergentes, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Tests de neutralisation, Évolution moléculaire dirigée.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (genetics), Antibodies, Viral (isolation & purification), Antibodies, Viral (therapeutic use), Antibody Specificity (immunology), Chlorocebus aethiops, Communicable Diseases, Emerging (prevention & control), Communicable Diseases, Emerging (therapy), Directed Molecular Evolution (methods), Drug Discovery, Humans, Mice, Mice, Inbred BALB C, Neutralization Tests, Point Mutation (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (therapy), Vero Cells.
- MESH :
- chemical , genetics : Antibodies, Viral.
- chemical , isolation & purification : Antibodies, Viral.
- chemical , therapeutic use : Antibodies, Viral.
- immunology : Antibody Specificity, Point Mutation, SARS Virus.
- methods : Directed Molecular Evolution.
- prevention & control : Communicable Diseases, Emerging, Severe Acute Respiratory Syndrome.
- therapy : Communicable Diseases, Emerging, Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Drug Discovery, Humans, Mice, Mice, Inbred BALB C, Neutralization Tests, Vero Cells.
Abstract
Using a comprehensive set of discovery and optimization tools, antibodies were produced with the ability to neutralize SARS coronavirus (SARS-CoV) infection in Vero E6 cells and in animal models. These anti-SARS antibodies were discovered using a novel DNA display method, which can identify new antibodies within days. Once neutralizing antibodies were identified, a comprehensive and effective means of converting the mouse sequences to human frameworks was accomplished using HuFR (human framework reassembly) technology. The best variant (61G4) from this screen showed a 3.5-4-fold improvement in neutralization of SARS-CoV infection in vitro. Finally, using a complete site-saturation mutagenesis methodology focused on the CDR (complementarity determining regions), a single point mutation (51E7) was identified that improved the 80% plaque reduction neutralization of the virus by greater than 8-fold. These discovery and evolution strategies can be applied to any emerging pathogen or toxin where a causative agent is known.
DOI: 10.1093/protein/gzn027
PubMed: 18480090
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B39
Links to Exploration step
pubmed:18480090Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.</title><author><name sortKey="Rogers, J" sort="Rogers, J" uniqKey="Rogers J" first="J" last="Rogers">J. Rogers</name><affiliation wicri:level="1"><nlm:affiliation>Verenium Corporation, 4955 Directors Place, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Verenium Corporation, 4955 Directors Place, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Schoepp, R J" sort="Schoepp, R J" uniqKey="Schoepp R" first="R J" last="Schoepp">R J Schoepp</name></author><author><name sortKey="Schroder, O" sort="Schroder, O" uniqKey="Schroder O" first="O" last="Schröder">O. Schröder</name></author><author><name sortKey="Clements, T L" sort="Clements, T L" uniqKey="Clements T" first="T L" last="Clements">T L Clements</name></author><author><name sortKey="Holland, T F" sort="Holland, T F" uniqKey="Holland T" first="T F" last="Holland">T F Holland</name></author><author><name sortKey="Li, J Q" sort="Li, J Q" uniqKey="Li J" first="J Q" last="Li">J Q Li</name></author><author><name sortKey="Li, J" sort="Li, J" uniqKey="Li J" first="J" last="Li">J. Li</name></author><author><name sortKey="Lewis, L M" sort="Lewis, L M" uniqKey="Lewis L" first="L M" last="Lewis">L M Lewis</name></author><author><name sortKey="Dirmeier, R P" sort="Dirmeier, R P" uniqKey="Dirmeier R" first="R P" last="Dirmeier">R P Dirmeier</name></author><author><name sortKey="Frey, G J" sort="Frey, G J" uniqKey="Frey G" first="G J" last="Frey">G J Frey</name></author><author><name sortKey="Tan, X" sort="Tan, X" uniqKey="Tan X" first="X" last="Tan">X. Tan</name></author><author><name sortKey="Wong, K" sort="Wong, K" uniqKey="Wong K" first="K" last="Wong">K. Wong</name></author><author><name sortKey="Woodnutt, G" sort="Woodnutt, G" uniqKey="Woodnutt G" first="G" last="Woodnutt">G. Woodnutt</name></author><author><name sortKey="Keller, M" sort="Keller, M" uniqKey="Keller M" first="M" last="Keller">M. Keller</name></author><author><name sortKey="Reed, D S" sort="Reed, D S" uniqKey="Reed D" first="D S" last="Reed">D S Reed</name></author><author><name sortKey="Kimmel, B E" sort="Kimmel, B E" uniqKey="Kimmel B" first="B E" last="Kimmel">B E Kimmel</name></author><author><name sortKey="Tozer, E C" sort="Tozer, E C" uniqKey="Tozer E" first="E C" last="Tozer">E C Tozer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18480090</idno><idno type="pmid">18480090</idno><idno type="doi">10.1093/protein/gzn027</idno><idno type="wicri:Area/PubMed/Corpus">001B39</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B39</idno><idno type="wicri:Area/PubMed/Curation">001B39</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B39</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.</title><author><name sortKey="Rogers, J" sort="Rogers, J" uniqKey="Rogers J" first="J" last="Rogers">J. Rogers</name><affiliation wicri:level="1"><nlm:affiliation>Verenium Corporation, 4955 Directors Place, San Diego, CA 92121, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Verenium Corporation, 4955 Directors Place, San Diego, CA 92121</wicri:regionArea></affiliation></author><author><name sortKey="Schoepp, R J" sort="Schoepp, R J" uniqKey="Schoepp R" first="R J" last="Schoepp">R J Schoepp</name></author><author><name sortKey="Schroder, O" sort="Schroder, O" uniqKey="Schroder O" first="O" last="Schröder">O. Schröder</name></author><author><name sortKey="Clements, T L" sort="Clements, T L" uniqKey="Clements T" first="T L" last="Clements">T L Clements</name></author><author><name sortKey="Holland, T F" sort="Holland, T F" uniqKey="Holland T" first="T F" last="Holland">T F Holland</name></author><author><name sortKey="Li, J Q" sort="Li, J Q" uniqKey="Li J" first="J Q" last="Li">J Q Li</name></author><author><name sortKey="Li, J" sort="Li, J" uniqKey="Li J" first="J" last="Li">J. Li</name></author><author><name sortKey="Lewis, L M" sort="Lewis, L M" uniqKey="Lewis L" first="L M" last="Lewis">L M Lewis</name></author><author><name sortKey="Dirmeier, R P" sort="Dirmeier, R P" uniqKey="Dirmeier R" first="R P" last="Dirmeier">R P Dirmeier</name></author><author><name sortKey="Frey, G J" sort="Frey, G J" uniqKey="Frey G" first="G J" last="Frey">G J Frey</name></author><author><name sortKey="Tan, X" sort="Tan, X" uniqKey="Tan X" first="X" last="Tan">X. Tan</name></author><author><name sortKey="Wong, K" sort="Wong, K" uniqKey="Wong K" first="K" last="Wong">K. Wong</name></author><author><name sortKey="Woodnutt, G" sort="Woodnutt, G" uniqKey="Woodnutt G" first="G" last="Woodnutt">G. Woodnutt</name></author><author><name sortKey="Keller, M" sort="Keller, M" uniqKey="Keller M" first="M" last="Keller">M. Keller</name></author><author><name sortKey="Reed, D S" sort="Reed, D S" uniqKey="Reed D" first="D S" last="Reed">D S Reed</name></author><author><name sortKey="Kimmel, B E" sort="Kimmel, B E" uniqKey="Kimmel B" first="B E" last="Kimmel">B E Kimmel</name></author><author><name sortKey="Tozer, E C" sort="Tozer, E C" uniqKey="Tozer E" first="E C" last="Tozer">E C Tozer</name></author></analytic><series><title level="j">Protein engineering, design & selection : PEDS</title><idno type="ISSN">1741-0126</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (genetics)</term><term>Antibodies, Viral (isolation & purification)</term><term>Antibodies, Viral (therapeutic use)</term><term>Antibody Specificity (immunology)</term><term>Chlorocebus aethiops</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Communicable Diseases, Emerging (therapy)</term><term>Directed Molecular Evolution (methods)</term><term>Drug Discovery</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Point Mutation (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Vero Cells</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (génétique)</term><term>Anticorps antiviraux (isolement et purification)</term><term>Anticorps antiviraux (usage thérapeutique)</term><term>Cellules Vero</term><term>Découverte de médicament</term><term>Humains</term><term>Maladies transmissibles émergentes ()</term><term>Mutation ponctuelle (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps (immunologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term><term>Évolution moléculaire dirigée ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Mutation ponctuelle</term><term>Spécificité des anticorps</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Specificity</term><term>Point Mutation</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Directed Molecular Evolution</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Communicable Diseases, Emerging</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Drug Discovery</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Découverte de médicament</term><term>Humains</term><term>Maladies transmissibles émergentes</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term><term>Évolution moléculaire dirigée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Using a comprehensive set of discovery and optimization tools, antibodies were produced with the ability to neutralize SARS coronavirus (SARS-CoV) infection in Vero E6 cells and in animal models. These anti-SARS antibodies were discovered using a novel DNA display method, which can identify new antibodies within days. Once neutralizing antibodies were identified, a comprehensive and effective means of converting the mouse sequences to human frameworks was accomplished using HuFR (human framework reassembly) technology. The best variant (61G4) from this screen showed a 3.5-4-fold improvement in neutralization of SARS-CoV infection in vitro. Finally, using a complete site-saturation mutagenesis methodology focused on the CDR (complementarity determining regions), a single point mutation (51E7) was identified that improved the 80% plaque reduction neutralization of the virus by greater than 8-fold. These discovery and evolution strategies can be applied to any emerging pathogen or toxin where a causative agent is known.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18480090</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1741-0126</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Protein engineering, design & selection : PEDS</Title><ISOAbbreviation>Protein Eng. Des. Sel.</ISOAbbreviation></Journal><ArticleTitle>Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.</ArticleTitle><Pagination><MedlinePgn>495-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/protein/gzn027</ELocationID><Abstract><AbstractText>Using a comprehensive set of discovery and optimization tools, antibodies were produced with the ability to neutralize SARS coronavirus (SARS-CoV) infection in Vero E6 cells and in animal models. These anti-SARS antibodies were discovered using a novel DNA display method, which can identify new antibodies within days. Once neutralizing antibodies were identified, a comprehensive and effective means of converting the mouse sequences to human frameworks was accomplished using HuFR (human framework reassembly) technology. The best variant (61G4) from this screen showed a 3.5-4-fold improvement in neutralization of SARS-CoV infection in vitro. Finally, using a complete site-saturation mutagenesis methodology focused on the CDR (complementarity determining regions), a single point mutation (51E7) was identified that improved the 80% plaque reduction neutralization of the virus by greater than 8-fold. These discovery and evolution strategies can be applied to any emerging pathogen or toxin where a causative agent is known.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Verenium Corporation, 4955 Directors Place, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoepp</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Schröder</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Clements</LastName><ForeName>T L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>T F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Dirmeier</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Woodnutt</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Kimmel</LastName><ForeName>B E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Tozer</LastName><ForeName>E C</ForeName><Initials>EC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01AI61 419-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Protein Eng Des Sel</MedlineTA><NlmUniqueID>101186484</NlmUniqueID><ISSNLinking>1741-0126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021821" MajorTopicYN="N">Communicable Diseases, Emerging</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019020" MajorTopicYN="N">Directed Molecular Evolution</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18480090</ArticleId><ArticleId IdType="pii">gzn027</ArticleId><ArticleId IdType="doi">10.1093/protein/gzn027</ArticleId><ArticleId IdType="pmc">PMC2461042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Methods. 2005 May;36(1):35-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15848073</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 May;79(9):5833-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15827197</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Fam Physician. 2006 Sep 1;74(5):783-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16970022</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 2007 Feb;44(5):680-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16824601</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Health Syst Pharm. 2007 Jan 15;64(2):149-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17215466</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2006 Nov;12(11):1657-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17283614</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Apr;81(8):4033-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17287272</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2007 Apr 25;361(1):93-102</Citation><ArticleIdList><ArticleId IdType="pubmed">17161858</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Today. 2000 Aug;21(8):397-402</Citation><ArticleIdList><ArticleId IdType="pubmed">10916143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2000 Dec;18(12):1251-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11101802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2002 Feb;20(2):114</Citation><ArticleIdList><ArticleId IdType="pubmed">11821846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2002 Sep;2(9):706-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12209139</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2003 Jan 5;305(1):201-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12504553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Jan;9(1):129-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12514726</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 2003 Aug;279(1-2):251-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12969565</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2003 Dec;112(6 Pt 1):1447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">14654628</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Toxicol Methods. 2004 Jan-Feb;49(1):39-55</Citation><ArticleIdList><ArticleId IdType="pubmed">14670693</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Sci. 2004 Feb;13(2):494-503</Citation><ArticleIdList><ArticleId IdType="pubmed">14718652</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 2004;388:3-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15289056</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1985 Feb;45(2):879-85</Citation><ArticleIdList><ArticleId IdType="pubmed">3871353</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1994 Feb 21;339(3):285-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8112468</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 1996 Jan;33(1):47-56</Citation><ArticleIdList><ArticleId IdType="pubmed">8604223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2005 May;36(1):43-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15848074</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001B39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:18480090
|texte= Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18480090" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |